

Senseera, an Israeli-based startup, has developed a novel liquid biopsy modality that analyzes cell-free nucleosomes - small particles composed of histone proteins and DNA that are derived from dying cells and found in blood. The technology can detect multiple pathologies in a single blood test, at a significantly lower cost than traditional methods. In recent years, Senseera has refined their assay and computational tools and successfully tested the technology on various clinical indications, such as early detection and subtyping of cancers and identifying non-cancer diseases. As a first business avenue, Senseera is working with Pharma and biotech companies to enhance their research and development efforts, and is now in the process of identifying the right indications for developing their first clinical products.